Five-year risks of CIN 3+ and cervical cancer among women who test pap-negative but are HPV-positive

Journal of Lower Genital Tract Disease

Volumn 17, Issue 5 SUPPL.1, 2013, Pages

  Katki, Hormuzd A ^a   Schiffman, Mark ^a   Castle, Philip E ^b   Fetterman, Barbara ^c   Poitras, Nancy E ^c   Lorey, Thomas ^c   Cheung, Li C ^d   Raine Bennett, Tina ^e   Gage, Julia C ^a   Kinney, Walter K ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Regional Laboratory   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e DIVISION OF RESEARCH   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

Cancer prevention; Cervical intraepithelial neoplasia (CIN); Human papillomavirus (HPV); Pap; Prospective cohort

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; UTERUS CARCINOMA; WART VIRUS;

ADULT; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIROLOGY;

EID: 84876132391     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e318285437b     Document Type: Article

References (24)

1. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370: 890-907.
3. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95: 46-52.
4. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 2012;16: 175-204.
5. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180: 1415-23.
6. Insinga RP, Perez G,WheelerCM, Koutsky LA, Garland SM, Leodolter S, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 2010;19: 1585-94.
7. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007;195: 1582-9.
8. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100: 513-7.
9. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12: 663-72.
10. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines J Low Genit Tract Dis 2013;17:S28YS35.
11. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287: 2114-9.
12. Lawless JF. Statistical Models and Methods for Lifetime Data. 2nd ed. Hoboken, NJ: Wiley-Interscience; 2003.
13. Turnbull B. The empirical distribution function with arbitrarily grouped, censored and truncated data. J Roy Stat Soc B 1976;38: 290-5.
14. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285: 1500-5.
15. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathologyreviewed diagnoses: an ALTS report. Am J Clin Pathol 2007; 127: 805-15.
16. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113: 18-25.
17. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116: 1373-80.
18. Kinney W, Fetterman B, Cox JT, Lorey T, Flanagan T, Castle PE. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol 2011;121: 309-13.
19. BulkmansNW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370: 1764-72.
20. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357: 1579-88.
21. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357: 1589-97.
22. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11: 249-57.
23. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 2011;136: 578-86.
24. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of cervical cancer and CIN 3+ among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis 2013;17:S36YS42.